LGALS1 and pulmonary fibrosis: Inhibition of Gal-1 expression in dermal fibroblasts (keloid), Müller cells (diabetic retinopathy), renal epithelial cells (diabetic nephropathy), hepatic stellate cells (liver fibrosis), pancreatic hepatic cells (pancreatic fibrosis) and epithelial alveolar cells (pulmonary fibrosis) is what should be developed for therapeutic applications against organ fibrosis progression.